News

Press Releases

October 27, 2025
China’s NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)

Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype […]

Read more
October 2, 2025
OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates

ROCKVILLE, Md., Oct. 02, 2025 — OncoC4, Inc. a clinical-stage biotechnology company, today announced the recent closing of a Series […]

Read more
September 8, 2025
OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer

PRESERVE-003 is evaluating gotistobart vs. docetaxel in patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed on chemotherapy […]

Read more
August 18, 2025
OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer

ROCKVILLE, Maryland, August 18, 2025 (GLOBE NEWSWIRE) –– OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today […]

Read more
July 28, 2025
OncoC4 Announces New Preclinical Data Highlighting ONC-841, a Novel SIGLEC 10 Antibody, as a Potential New Class of Therapeutics for Alzheimer’s Disease

SIGLEC 10 identified as a genetic driver for amyloid plaque formation in mice ONC-841 blockade reduced amyloid plaques, normalized microglia […]

Read more
Scroll to Top